Why it’s time to say goodbye to stavudine ... everywhere
Southern African Journal of HIV Medicine
| Field | Value | |
| Title | Why it’s time to say goodbye to stavudine ... everywhere | |
| Creator | Andrieux-Meyer, Isabelle Clayden, Polly Collins, Simon Geffen, Nathan Goemaere, Eric Harrington, Mark Lynch, Sharonann von Schoen-Angerer, Tido Swan, Tracy | |
| Description | The previous issue of the SAJHIV (December 2011) carried an Opinion piece by Innes, Cotton and Venter regarding the potential value of low-dose of stavudine (20 mg twice a day). They suggested that reduced dosing of stavudine may lead to levels of viral suppression comparable with those achieved with stavudine 30 mg bd but with a lower risk of toxicity and side-effects, and at a fraction of the cost of tenofovir. The Opinion was related to a larger proposal, led by Venter, to conduct a head-to-head trial comparing low-dose stavudine with tenofovir (both in a regimen including lamivudine and efavirenz) on viral suppression and other treatment outcomes over 24 months. There has been considerable debate regarding the advantages and disadvantages of low-dose stavudine, and in turn the value of any such trial. Here the debate continues with a commentary by Isabelle Andrieux-Meyer et al. and a rebuttal by Venter and colleagues. | |
| Publisher | AOSIS | |
| Date | 2012-03-13 | |
| Identifier | 10.4102/sajhivmed.v13i1.155 | |
| Source | Southern African Journal of HIV Medicine; Vol 13, No 1 (2012); 17-19 2078-6751 1608-9693 | |
| Language | eng | |
| Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://sajhivmed.org.za/index.php/hivmed/article/view/155/259
https://sajhivmed.org.za/index.php/hivmed/article/view/155/258
|
|
ADVERTISEMENT
